Although the ability of forskolin to prevent tumour colonisation and metastasis was reported previously (Agarwal and Parks, 1983), our work for the first time underscores the therapeutic relevance of PP2A-activating drugs in cancer by specifically indicating that treatment of leukaemic mice with forskolin or 1,9-dideoxy forskolin remarkably prolongs the lifespan and decreases the leukaemia burden to a point in which no BCR/ABL+ cells are detected in peripheral blood of treated animals (Neviani et al, 2005). Here, BCR is linked to leukemia.